Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Takeda, Amylin End Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Takeda, Amylin End Pact

Commercial prospects sink obesity combo

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Takeda Pharmaceutical Co. and Amylin Pharmaceuticals have mutually terminated their worldwide agreement to co-develop and commercialize compounds for obesity. The pact began in October 2009, .

The companies announced in August 2011 their decision to discontinue the development of pramlintide/metreleptin, an investigational combination therapy for the treatment of obesity. That joint decision was based on a commercial reassessment of the pramlintide/metreleptin program, which had been in Phase II development as a twice-a-day injection formulation. The companies have since decided to formally terminate the partnership at this time. Amylin was purchased by Bristol-Myers Squibb and AstraZeneca in June 2012.

Takeda released a statement that read, “Having greatly benefited from the Amylin team’s collective experience and scientific expertise, Takeda will continue to enhance its R&D activities in the area of obesity as well as its other core therapeutic areas to meet the needs of patients.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics